For more than a decade, Oncotest-Teva has been focused on identifying new approaches to diagnosing malignancies and predicting the course of a disease according to the unique genetic profile of the patient and the tumour cells, as well as on more precise and effective combination of therapeutic directions. For patients, the test allows them to know and understand their tumour, and allows physicians to customize the treatment for a specific patient. Over the years, the Oncotest-Teva team has carefully selected the strongest and most significant molecular tests together with the world's leading laboratories to help patients and their treatment teams make therapeutic decisions based on the most up-to-date and reliable information.
Through our collaboration with Oncotest-Teva, Bridge Medical provides patients with the latest and best tools to get the answers they need: what is the chance of cancer recurrence? Do they need chemotherapy? What type of chemotherapy or biological drugs can treat their tumour? The tests also reveal genetic mutations that are inherited by the patient's children and other relatives.